Abstract
Advances in recombinant DNA technology have made possible the advent of a new generation of safer, better-defined subunit vaccines. Because vaccines based on these weakly immunogenic antigens require an adjuvant for efficacy, we undertook the development of a safe and efficacious adjuvant suitable for widespread human administration. Vaccines formulated with aluminum salts (alum), the only adjuvant thus far utilized with vaccines approved in the United States for human administration, were necessarily adopted as a benchmark for the minimum acceptable activity of a new adjuvant. Our goal was to develop an adjuvant that significantly exceeded aluminum hydroxide in potency, while retaining equally low toxicity. By the early 1990s a wide variety of approaches to adjuvant development had been described (Allison and Byars, 1990; Edelman, 1980; Gregoriadis and Panagiotidi, 1989; Warren et al., 1986). Two major mechanisms of adjuvant activity have been repeatedly cited in this literature: the depot effect, whereby long-term release of antigen results in increased immune response; and coadministration of immunostimulators, which specifically activate portions of the immune system in, as yet, incompletely defined fashions. The prototypic strong adjuvant, complete Freund’s adjuvant (CFA), combined these functions by releasing a mixture of immunostimulatory mycobacterial cell wall components along with antigen from a water/mineral oil/Arlacel A emulsion depot over an extended period of time (Freund, 1956). CFA remains the reference standard for potent adjuvant activity; however, it is now considered too toxic in many cases for use even in laboratory animals. In addition to the aluminum salts, several adjuvants based on the depot effect alone have been studied. These include incomplete Freund’s adjuvant (IFA), which lacks the potent, but toxic, cell wall components, and Adjuvant 65 (water/peanut oil/mannide monooleate), a yet further detoxified water/oil formulation (Hilleman et al., 1972a,b). Despite extensive study, neither formulation was approved for human administration. We chose to avoid water/oil emulsions. A more recent version of the depot approach, controlled release of antigen from synthetic polymer microspheres, remains a promising area of study (Cohen et al., 1991; O’Hagan et al., 1991) but appears to have an unacceptably long development time for our purposes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allison, A., and Byars, N., 1987, Vaccine technology: Adjuvants for increased efficacy, Biotechnology 5:1043–1045.
Allison, A. C., and Byars, N. E., 1990, Adjuvant formulations and their mode of action, Semin. Immunol. 2:369–374.
Audibert, F. M., Parant, C., Damais, C., Lefrancier, P., Denien, M., Choay, J., and Chedid, L., 1980, Disassociation of immunostimulating activities of muramyldipeptide (MDP) by linking of amino acids or peptides to the glutaminyl residue, Biochem. Biophys. Res. Commun. 96:915–923.
Boyd, J., Parkinson, C., and Sherman, P., 1972, Factors affecting emulsion stability and the HLB concept, J. Colloid Interfac. Sci. 41:359–370.
Brynestad, K., Babbit, B., Huang, L., and Rouse, B. T., 1990, Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1–23 peptide of glycoprotein D of herpes simplex virus: Implications for subunit vaccines, J. Virol. 64:680–685.
Byars, N. E., and Allison, A. C., 1987, Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity, Vaccine 5:223–228.
Byars, N. E., Allison, A. C., Harmon, M. W., and Kendal, A. P., 1990, Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation, Vaccine 8:49–56.
Cohen, S., Yoshioka, T., Lucarelli, M., Hwang, L., and Langer, R., 1991, Controlled delivery systems for proteins based on poly (lactic/glycolic acid) microspheres, Pharm. Res. 8:713–720.
Edelman, R., 1980, Vaccine adjuvants, Rev Infect. Dis. 2:370–383.
Fidler, I., 1988, Targetting of immunomodulators to mononuclear phagocytes for therapy in cancer, Adv. Drug Deliv. Res. 1:69–76.
Fidler, I. J., Sone, S., Fogler, W. F., and Barnes, Z. L., 1981, Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl tripeptide, Proc. Natl. Acad. Sci. USA 78:1680–1684.
Freund, J., 1956, The mode of action of immunologic adjuvants, Adv. Tuberc. Res. 7:130–148.
Gisler, R. H., Shumann, G., Sackman, W., Pericin, C., Tarcsay, L., and Dietrich, F M., 1986, A novel muramyl peptide, MTP-PE: Profile of biological activities, in: Immunomodulation by Microbial Products and Related Synthetic Compounds (Y K. S. Yamamura, ed.), Excerpta Medica, Amsterdam, pp. 167–170.
Gregoriadis, G., and Manesis, E. K., 1980, Liposomes as immunological adjuvants for hepatitis B surface antigens, in: Liposomes and Immunology (H. Six, ed.), Elsevier/North Holland, Amsterdam, pp. 271–283.
Gregoriadis, G., and Panagiotidi, C., 1989, Immunoadjuvant action of liposomes: Comparison with other adjuvants, Immunol. Lett. 20:237–240.
Hilleman, M. R., Woodhour, A., Friedman, A., Weibel, R. E., and Stokes, J., Jr., 1972a, The clinical application of adjuvant 65, Ann. Allergy 30:152–158.
Hilleman, M. R., Woodhour, A. F., Friedman, A., and Phelps, A. H., 1972b, Studies for safety of adjuvant 65, Ann. Allergy 30:477–483.
Hunter, R., and Bennett, B., 1984, The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers, J. Immunol. 133:3167–3175.
Hunter, R., Strickland, F., and Kezdy, F., 1981, The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile lipophile balance, J. Immunol. 127:1244–1250.
Inselberg, J., Bathurst, I., Konsopon, J., Barchfeld, G., Barr, P., and Rosau, R., 1993, Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: Adjuvant effects on induction of protective immunity, Infect. Immun. 61:2041–2047.
Kossovsky, N., Gelman, A., Sponsler, E., and Millett, D., 1991, Nanocrystalline Epstein-Barr virus decoys, J. Appl. Biomater. 2:251–259.
Kotani, S., Watanabe, Y., Kinoshita, F., Shimono, T., Morisaki, I., Shiba, T., Kusumoto, S., Tarumi, Y., and Ikenaka, K., 1975, Immunoadjuvant activities of synthetic N-acetylmuramyl peptides or amino acids, Biken J. 18:105–111.
Kreuter, J., Berg, U., Liehl, E., Soliva, M., and Speiser, P. P., 1986, Influence of the particle size on the adjuvant effect of paniculate polymeric adjuvants, Vaccine 4:125–129.
Kreuter, J., Liehl, E., Berg, U., Soliva, M., and Speiser, P. P., 1988, Influence of hydrophobicity on the adjuvant effect of particulate polymeric adjuvants, Vaccine 6:253–256.
Lidgate, D., Trattner, T., Schultz, R., and Maskiewicz, R., 1992, Sterile filtration of a parenteral emulsion, Pharm. Res. 9:860–863.
Masihi, K. N., Lange, W., Brehmer, W., and Ribi, E., 1986, Immunobiological activities of nontoxic lipid A: Enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects, Int. J. Immunopharmacol. 8:339–345.
Merser, C., Sinay, P., and Adam, A., 1975, Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives, Biochem. Biophys. Res. Commun. 66:1316–1322.
O’Hagan, D. T., Jeffery, H., Roberts, M. J., McGee, J. P., and Davis, S. S., 1991, Controlled release microparticles for vaccine development, Vaccine 9:768–771.
Ott, G., Van Nest, G., and Burke, R. L., 1992, The use of muramyl peptides as vaccine adjuvants, in: Vaccine Research and Developments (W. Koff and H. Six, eds.), Dekker, New York, pp. 89–114.
Ribi, E., Takayama, K., Milner, K., Gray, G. R., Goren, M., Parker, R., McLaughlin, C., and Kelly, M., 1976, Regression of tumors by an endotoxin combined with trehalose mycolates of differing structure, Cancer Immunol. Immunother. 1:265–270.
Sanchez-Pescador, L., Burke, R. L., Ott, G., and Van Nest, G., 1988, The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine, J. Immunol. 141:1720–1727.
Tsujimoto, M., Kotani, S., Kinoshita, F., Karoh, S., Shiba, T., and Kusumoto, S., 1986, Adjuvant activity of 6-O-acyl-muramyldipeptides to enhance primary cellular and humoral immune responses in guinea pigs: Adaptability to various vehicles and pyrogenicity, Infect. Immun. 53:511–516.
Ullrich, S., and Fidler, I., 1992, Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens, J. Leukocyte Biol. 52:489–494.
Van Nest, G., Steimer, K., Haigwood, N., Burke, R., and Ott, G., 1992, Advanced adjuvant formulations for use with recombinant subunit vaccines, in: Vaccines 92, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 57–62.
Warren, H. S., Vogel, F. R., and Chedid, L. A., 1986, Current status of immunological adjuvants, Annu. Rev. Immunol. 4:369–388.
White, R. G., Jolies, P., Samour, D., and Lederer, E., 1964, Correlation of adjuvant activity and chemical structure of wax D fractions of mycobacteria, Immunology 7:158–163.
Wintsch, J., Chaignat, C. L., Braun, D. G., Jeannet, M., Stalder, H., and Abrignani, S., 1991, Safety and immunogenicity of a genetically engineered human immunodeficiency vaccine, J. Infect. Dis. 163:219–225.
Woodward, L., 1989, Adjuvant activity of water-insoluble surfactants, Lab. Anim. Sci. 39:222–225.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ott, G., Barchfeld, G.L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., Van Nest, G. (1995). MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines. In: Powell, M.F., Newman, M.J. (eds) Vaccine Design. Pharmaceutical Biotechnology, vol 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1823-5_10
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1823-5_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5737-7
Online ISBN: 978-1-4615-1823-5
eBook Packages: Springer Book Archive